Pulmonology Medical News about cost-effectiveness

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
The European Journal of Health Economics, 08/04/09

Persson U et al. – Ex ante VBP assessment is a form of risk sharing, which has been used by TLV to speed up reimbursement and dispersion of effective new drugs despite uncertainty in their true cost–effectiveness. Manufacturers are often asked in return to generate additional health economic evidence that will establish cost–effectiveness as part of ex post review. The alternative is to delay the reimbursement approval until satisfactory evidence is available.

<< Previous
Fatal Massive Cerebral Air Embolism in a Lung Transplant Patient

Next >>
Hospital-Acquired Pneumonia Developed in Non-Intensive Care Units